Literature DB >> 19509496

The spectrum of peripheral T-cell lymphomas.

Hilary O'leary1, Kerry J Savage.   

Abstract

PURPOSE OF REVIEW: This review summarizes recent progress that has advanced our understanding of the pathobiology and prognosis of peripheral T-cell lymphomas including the changes introduced to the updated World Health Organization classification of lymphoid neoplasms. RECENT
FINDINGS: The International Peripheral T-Cell Lymphoma Project was a large collaborative project, highlighting the clinico-pathologic and geographic differences of this diverse group of diseases. Peripheral T-cell lymphoma, not otherwise specified, is a biologically heterogeneous subtype, and a number of studies including investigations using molecular profiling have explored whether meaningful prognostic or biologic subgroups can be identified. Angioimmunoblastic T-cell lymphoma demonstrates overlapping immunophenotypical and molecular features with normal follicular T-helper cells, giving some insight into the cell of origin. Systemic anaplastic large cell lymphoma is composed of two disease groups based on the presence or absence of anaplastic lymphoma kinase overexpression. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma has a significantly better prognosis than anaplastic lymphoma kinase-negative anaplastic large cell lymphoma and molecular studies have illustrated that each entity has a distinct molecular profile. Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma has been recently shown to have a more favourable, but still unsatisfactory, prognosis than peripheral T-cell lymphoma, not otherwise specified, and biological and molecular distinctions confirm that they are separate entities.
SUMMARY: Advances are being made in understanding the unique pathobiology of the peripheral T-cell lymphoma subtypes that will help to refine diagnoses, identify potential prognostic markers, elucidate the molecular mechanisms critical in disease pathogenesis and define new therapeutic targets in the poor-risk population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509496     DOI: 10.1097/MOH.0b013e32832b89a9

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  9 in total

1.  Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.

Authors:  Andrés E Quesada; Nghia D Nguyen; Adan Rios; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

2.  Identification of Hub Genes and Key Pathways Associated with Peripheral T-cell Lymphoma.

Authors:  Hai-Xia Gao; Meng-Bo Wang; Si-Jing Li; Jing Niu; Jing Xue; Jun Li; Xin-Xia Li
Journal:  Curr Med Sci       Date:  2020-10-29

3.  Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma.

Authors:  J H Yi; J H Kim; K K Baek; T Lim; D J Lee; Y C Ahn; K Kim; S J Kim; Y H Ko; W S Kim
Journal:  Ann Oncol       Date:  2011-01-10       Impact factor: 32.976

Review 4.  Biology and management of rare primary extranodal T-cell lymphomas.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Oncology (Williston Park)       Date:  2010-01       Impact factor: 2.533

5.  PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.

Authors:  Esperanza Martín-Sánchez; Lina Odqvist; Socorro M Rodríguez-Pinilla; Margarita Sánchez-Beato; Giovanna Roncador; Beatriz Domínguez-González; Carmen Blanco-Aparicio; Ana M García Collazo; Esther González Cantalapiedra; Joaquín Pastor Fernández; Soraya Curiel del Olmo; Helena Pisonero; Rebeca Madureira; Carmen Almaraz; Manuela Mollejo; F Javier Alves; Javier Menárguez; Fernando González-Palacios; José Luis Rodríguez-Peralto; Pablo L Ortiz-Romero; Francisco X Real; Juan F García; James R Bischoff; Miguel A Piris
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

Review 6.  The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.

Authors:  Ines Garces de Los Fayos Alonso; Huan-Chang Liang; Suzanne D Turner; Sabine Lagger; Olaf Merkel; Lukas Kenner
Journal:  Cancers (Basel)       Date:  2018-03-28       Impact factor: 6.639

7.  Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B).

Authors:  Derek Murphy; Jeremy Parker; Minglong Zhou; Faisal M Fadlelmola; Christian Steidl; Aly Karsan; Randy D Gascoyne; Hong Chen; Diponkar Banerjee
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

8.  Comorbidity as an independent prognostic factor in elderly patients with peripheral T-cell lymphoma.

Authors:  Haifeng Zhao; Tengteng Wang; Yafei Wang; Yong Yu; Xiaofan Wang; Zhigang Zhao; Hongliang Yang; Bei Yan; Xiaoxiong Wu; Wanming Da; Yizhuo Zhang
Journal:  Onco Targets Ther       Date:  2016-03-24       Impact factor: 4.147

9.  Anaplastic lymphoma kinase negative anaplastic large cell lymphoma of hard palate as first clinical manifestation of acquired immune deficiency syndrome.

Authors:  Anjali Narwal; Achla Bharti Yadav; Sant Prakash; Shally Gupta
Journal:  Contemp Clin Dent       Date:  2016 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.